Business Wire03.21.18
4Tech Inc., a developer of transcatheter tricuspid valve repair, has appointed Tom Fleming as president and CEO; and Keith D. Dawkins, M.D., as chief medical officer (CMO). Fleming replaces Mike Ennen, who is stepping down for family reasons. This new leadership team enhances the company's strategy to advance its clinical program for TriCinch Coil System.
Tom Fleming comes to 4Tech with over 21 years of experience at Boston Scientific Corp. in numerous roles of increasing responsibility, including vice president and general manager for Transcatheter Aortic Valves, Program Management, Interventional Cardiology, Cardiac Rhythm Management and Peripheral Interventions. He also held leadership roles in Imaging, Embolic Protection, Quality, and Marketing. In his most recent role as vice president and general manager for Transcatheter Aortic Valves from 2012 - 2017, he was responsible for leading Boston Scientific into the $3 billion global market for minimally invasive transcatheter aortic valves. With clinical investigators and Boston Scientific team, he successfully drove the execution of the first comparative head-to-head randomized U.S. investigative device exemption trial, which demonstrated superiority at one year.
Dawkins served as executive vice president and global chief medical officer at Boston Scientific for all divisions from 2012 to 2017, where he was responsible for enhancing the company’s global clinical programs and strategies. Previously, he served as senior vice president and CMO for Boston Scientific's Cardiology Rhythm and Vascular Group. Prior to joining Boston Scientific, Dawkins was a practicing interventional cardiologist for over 20 years in England. He has earned a series of clinical, research and academic distinctions, including a post-doctoral research fellowship at Stanford University as a Fulbright Scholar. Dawkins also served as president of the British Cardiovascular Intervention Society and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.
4Tech Inc. is a privately held clinical-stage company incorporated in Delaware, with operations in Galway, Ireland (4Tech Cardio Ltd). The company is dedicated to developing a minimally invasive transcatheter solution for the treatment of functional tricuspid regurgitation.
Tom Fleming comes to 4Tech with over 21 years of experience at Boston Scientific Corp. in numerous roles of increasing responsibility, including vice president and general manager for Transcatheter Aortic Valves, Program Management, Interventional Cardiology, Cardiac Rhythm Management and Peripheral Interventions. He also held leadership roles in Imaging, Embolic Protection, Quality, and Marketing. In his most recent role as vice president and general manager for Transcatheter Aortic Valves from 2012 - 2017, he was responsible for leading Boston Scientific into the $3 billion global market for minimally invasive transcatheter aortic valves. With clinical investigators and Boston Scientific team, he successfully drove the execution of the first comparative head-to-head randomized U.S. investigative device exemption trial, which demonstrated superiority at one year.
Dawkins served as executive vice president and global chief medical officer at Boston Scientific for all divisions from 2012 to 2017, where he was responsible for enhancing the company’s global clinical programs and strategies. Previously, he served as senior vice president and CMO for Boston Scientific's Cardiology Rhythm and Vascular Group. Prior to joining Boston Scientific, Dawkins was a practicing interventional cardiologist for over 20 years in England. He has earned a series of clinical, research and academic distinctions, including a post-doctoral research fellowship at Stanford University as a Fulbright Scholar. Dawkins also served as president of the British Cardiovascular Intervention Society and held numerous appointments on hospital, regional and national committees, including the National Institute for Health and Clinical Excellence (NICE). He has been an author on more than 750 academic publications and presentations on a variety of cardiac topics.
4Tech Inc. is a privately held clinical-stage company incorporated in Delaware, with operations in Galway, Ireland (4Tech Cardio Ltd). The company is dedicated to developing a minimally invasive transcatheter solution for the treatment of functional tricuspid regurgitation.
